NYSE:MD - MEDNAX Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $26.33 -0.54 (-2.01 %) (As of 05/23/2019 08:55 AM ET)Previous Close$26.87Today's Range$26.16 - $26.8152-Week Range$25.47 - $48.77Volume521,561 shsAverage Volume1.14 million shsMarket Capitalization$2.28 billionP/E Ratio7.50Dividend YieldN/ABeta0.59 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and their unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of December 31, 2018, it had a network of approximately 4,210 affiliated physicians. The company was founded in 1979 and is based in Sunrise, Florida. Receive MD News and Ratings via Email Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Hospitals Sub-IndustryHealth Care Services SectorMedical Current SymbolNYSE:MD Previous SymbolNYSE:PDX CUSIP58502B10 CIK893949 Webhttp://www.mednax.com/ Phone954-384-0175Debt Debt-to-Equity Ratio0.79 Current Ratio2.55 Quick Ratio2.55Price-To-Earnings Trailing P/E Ratio7.50 Forward P/E Ratio8.36 P/E Growth1.02 Sales & Book Value Annual Sales$3.65 billion Price / Sales0.62 Cash Flow$4.7960 per share Price / Cash Flow5.49 Book Value$32.12 per share Price / Book0.82Profitability EPS (Most Recent Fiscal Year)$3.51 Net Income$268.62 million Net Margins-1.05% Return on Equity9.82% Return on Assets5.08%Miscellaneous Employees7,625 Outstanding Shares86,540,000Market Cap$2.28 billion Next Earnings Date8/1/2019 (Estimated) OptionableOptionable MEDNAX (NYSE:MD) Frequently Asked Questions What is MEDNAX's stock symbol? MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD." How were MEDNAX's earnings last quarter? MEDNAX Inc (NYSE:MD) announced its quarterly earnings data on Thursday, May, 2nd. The company reported $0.58 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.63 by $0.05. The company earned $851.20 million during the quarter, compared to the consensus estimate of $906.35 million. MEDNAX had a negative net margin of 1.05% and a positive return on equity of 9.82%. MEDNAX's revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.89 EPS. View MEDNAX's Earnings History. When is MEDNAX's next earnings date? MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for MEDNAX. What guidance has MEDNAX issued on next quarter's earnings? MEDNAX updated its second quarter 2019 earnings guidance on Thursday, May, 2nd. The company provided EPS guidance of $0.84-0.92 for the period, compared to the Thomson Reuters consensus estimate of $0.95. What price target have analysts set for MD? 11 brokerages have issued 1 year price targets for MEDNAX's stock. Their predictions range from $31.00 to $50.00. On average, they anticipate MEDNAX's share price to reach $40.5455 in the next twelve months. This suggests a possible upside of 54.0% from the stock's current price. View Analyst Price Targets for MEDNAX. What is the consensus analysts' recommendation for MEDNAX? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX. Has MEDNAX been receiving favorable news coverage? News headlines about MD stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MEDNAX earned a news impact score of -3.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. Who are some of MEDNAX's key competitors? Some companies that are related to MEDNAX include Encompass Health (EHC), Healthscope (HSO), Select Medical (SEM), Magellan Health (MGLN), Primary Health Care (PRY), Medical Facilities (DR), Capitol Health (CAJ), Animalcare Group (ANCR), SunLink Health Systems (SSY), Spine Injury Solutions (SPIN) and THC Biomed Intl (THC). What other stocks do shareholders of MEDNAX own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Dominion Energy (D), Gilead Sciences (GILD), Boeing (BA), Chevron (CVX), Walt Disney (DIS), General Electric (GE), JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK), Pfizer (PFE) and Visa (v). Who are MEDNAX's key executives? MEDNAX's management team includes the folowing people: Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 72)Mr. Joseph M. Calabro, Pres (Age 58)Mr. Stephen D. Farber, Exec. VP & CFO (Age 49)Mr. David A. Clark, Chief Operating Officer (Age 52)Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 50) Who are MEDNAX's major shareholders? MEDNAX's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.75%), Dimensional Fund Advisors LP (4.24%), ArrowMark Colorado Holdings LLC (2.86%), Nordea Investment Management AB (2.79%), Pzena Investment Management LLC (2.60%) and FMR LLC (1.69%). Company insiders that own MEDNAX stock include Cesar L Alvarez, David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX. Which major investors are selling MEDNAX stock? MD stock was sold by a variety of institutional investors in the last quarter, including Blue Harbour Group L.P., Pzena Investment Management LLC, Hsbc Holdings PLC, New York State Common Retirement Fund, FMR LLC, Fort Washington Investment Advisors Inc. OH, FIL Ltd and Morgan Stanley. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt and Vivian Lopez-Blanco. View Insider Buying and Selling for MEDNAX. Which major investors are buying MEDNAX stock? MD stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Lazard Asset Management LLC, Nordea Investment Management AB, Goldman Sachs Group Inc., AQR Capital Management LLC, First Trust Advisors LP, Neuberger Berman Group LLC and ArrowMark Colorado Holdings LLC. View Insider Buying and Selling for MEDNAX. How do I buy shares of MEDNAX? Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is MEDNAX's stock price today? One share of MD stock can currently be purchased for approximately $26.33. How big of a company is MEDNAX? MEDNAX has a market capitalization of $2.28 billion and generates $3.65 billion in revenue each year. The company earns $268.62 million in net income (profit) each year or $3.51 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe. What is MEDNAX's official website? The official website for MEDNAX is http://www.mednax.com/. How can I contact MEDNAX? MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected] MarketBeat Community Rating for MEDNAX (NYSE MD)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 436 (Vote Outperform)Underperform Votes: 464 (Vote Underperform)Total Votes: 900MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Put Option Volume Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.